Radius Health, Inc. (NASDAQ: RDUS), a biopharmaceutical company committed to developing unique therapeutics in osteoporosis, oncology, and endocrine diseases, recently announced that the positive results of it phase 3 ACTIVE trial were published in the Journal of the American Medical Association (JAMA). ACTIVE stands for Abaloparatide Comparator Trial InVertebral Endpoints. Abaloparatide is a drug being trialed for the treatment of postmenopausal women with osteoporosis. The trial involved 2,463 patients and was put in place to establish whether or not the drug was both safe and efficient.
In a news release, Dr. Paul Miller, medical director of the Colorado Center for Bone Research and lead author of the paper, had this to say: “The landmark ACTIVE trial results are important and further validate Abaloparatide’s potential to consistently, substantially and rapidly reduce both new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.”
Dr. Lorraine A. Fitzpatrick, chief medical officer of Radius, responded: “We are honored to have these findings published in JAMA, and are encouraged by the totality of data collected to date which demonstrate that Abaloparatide, if approved, could have a significant impact on improving outcomes for women with postmenopausal osteoporosis. We look forward to presenting additional scientific information about Abaloparatide as part of the American Society for Bone Mineral Research (ASBMR) Annual Meeting in Atlanta, Georgia September 16-19, 2016.”
The published results of the phase 3 ACTIVE trial showed that women treated with Abaloparatide on a daily basis for a year and a half did not have as many problems relating to new vertebral and nonvertebral fractures compared to those who were given a placebo replacement.
According to Miller, approximately two million women are affected by osteoporotic fractures each year in the United States, a number that between 2010 and 2030 is expected to grow by more than 20%, according to the NOF Prevalence Map 2014 (http://nnw.fm/5kG1Q). Because there is a great unmet medical need for therapies in this field and the safety and efficacy of Abaloparatide has not yet been determined, a New Drug Application is currently under review by the U.S. Food & Drug Administration.
For more information, visit www.RadiusPharm.com
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing network of more than 5,000 key distribution outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
